BioVie Chief Medical Officer Dr. Joe Palumbo joins Natalie Stoberman from the Proactive studios to share more details behind the biotech company's work on Parkinson's, Alzheimer's and Cirrhosis treatments.
BioVie is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation that leads to neuroinflammation and insulin resistance, but not their homeostatic functions like insulin signaling, neuron growth and survival. Both are drivers of Alzheimer’s and Parkinson’s diseases.